ERBB2 and obstructive sleep apnea syndrome: Following successful pre-clinical studies in murine models of OSA [47,138], which demonstrated the ability of HER2-targeted CAR-T cell therapy to kill OSA cells and derived metastases, this strategy has also been evaluated in human patients affected by recurrent OSA.